Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-23, Stock:ABBV, The news for the past five days is as follows:
2018-04-16: NEWS1: How AbbVie’s Humira Performed in 4Q17 and 2017.NEWS2: Upadacitinib Could Drive AbbVie’s Long-Term Growth.NEWS3: How AbbVie Performed in 4Q17 and Fiscal 2017.NEWS4: Vanguard S&P 500 ETF Experiences Big Outflow.NEWS5: Vanguard S&P 500 ETF Experiences Big Outflow.NEWS6: Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group — Fundamental Analysis, Key Performance Indications.NEWS7: Johnson & Johnson’s Revenue Estimates for 1Q18.
2018-04-17: NEWS1: AbbVie Inc. Is a Clear Value Play in Biotech Stocks.NEWS2: AbbVie Inc. Is a Clear Value Play in Biotech Stocks.NEWS3: Top Analyst Reports for AbbVie, Berkshire & PepsiCo.NEWS4: 7 Stock Picks With Giant Upside: Goldman.NEWS5: J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance.NEWS6: J&J (JNJ) Tops Q1 Earnings Estimates, Raises Sales Guidance.NEWS7: 5 Drug Stocks Poised to Surpass on Earnings This Quarter.NEWS8: Shire Sells Oncology Unit Ahead of Takeda's Potential Offer.NEWS9: Shire Sells Oncology Unit Ahead of Takeda's Potential Offer.NEWS10: Novartis’s 1Q18: Analysts Expect Revenue Growth.NEWS11: Updates on AbbVie’s AndroGel, Lupron, and Kaletra.NEWS12: Risankizumab Could Be AbbVie’s Long-Term Growth Driver.NEWS13: AbbVie’s Imbruvica in 4Q17 and Fiscal 2017.
2018-04-18: NEWS1: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.NEWS2: Gilead Sciences May Witness Significant Drop in Revenues in 2018.NEWS3: What Analysts Recommend for Gilead Sciences in April 2018.NEWS4: The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox.NEWS5: The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox.NEWS6: Analysts’ Recommendations for AbbVie in April 2018.NEWS7: AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference.NEWS8: AbbVie’s Duodopa, Creon, Synagis, Synthroid, and Sevoflurane.NEWS9: The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox.NEWS10: 5 Drug Stocks Poised to Surpass on Earnings This Quarter.NEWS11: 5 Drug Stocks Poised to Surpass on Earnings This Quarter.
2018-04-19: NEWS1: Mylan NV Could Be Closer to a Breakout Than Most Traders Realize.NEWS2: Gilead Sciences Expects Decline in Earnings in Fiscal 2018.NEWS3: Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising.NEWS4: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.NEWS5: Roche Hemophilia Drug Gets Breakthrough Therapy Designation.
2018-04-20: NEWS1: J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?.NEWS2: J&J, Novartis' Q1 Earnings Impress: Will Others Follow Suit?.NEWS3: AbbVie And Other Great Pharma And Biotech Income Stocks.

Answer: Rise